MondegarAI
RTW INVESTMENTS, LP

Q2 2025 · 13F-HR

RTW INVESTMENTS, LPholdings as filed

Filed 2025-08-14 · accession 0001493215-25-000007

$7.02B
Reported value
73
Positions
2025-06-30
Period end
View analyzed profile →PRO

The Brief · RTW INVESTMENTS, LP · Q2 2025

AI · grounded in 13F

RTW INVESTMENTS, LP established a new position in Madrigal Pharmaceuticals Inc MDGL valued at $603.4M. The fund also initiated new stakes in Natera Inc NTRA for $438.2M and PTC Therapeutics Inc PTCT for $378.3M. Other new additions include Argenx SE ARGX and Protagonist Therapeutics Inc PTGX.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
558868105MDGLMADRIGAL PHARMACEUTICALS INC$603.4M8.59%1,993,687CommonSOLE
632307104NTRANATERA INC$438.2M6.24%2,593,645CommonSOLE
69366J200PTCTPTC THERAPEUTICS INC$378.3M5.39%7,746,415CommonSOLE
04016X101ARGXARGENX SE$371.2M5.29%673,497CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$318.1M4.53%5,756,277CommonSOLE
457669307INSMINSMED INC$310.4M4.42%3,084,558CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$292.3M4.16%5,477,561CommonSOLE
925050106VRNAVERONA PHARMA PLC$288.6M4.11%3,051,878CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$273.2M3.89%9,618,845CommonSOLE
863667101SYKSTRYKER CORPORATION$233.6M3.33%590,517CommonSOLE
70975L107PENPENUMBRA INC$221.6M3.16%863,553CommonSOLE
N5749R1002GHMERUS N V$210.4M3.00%4,000,553CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$194.0M2.76%8,995,547CommonSOLE
98887Q104ZLABZAI LAB LTD$193.6M2.76%5,536,876CommonSOLE
05464T104AXSMAXSOME THERAPEUTICS INC$158.3M2.26%1,516,903CommonSOLE
750491102RDNTRADNET INC$153.1M2.18%2,690,344CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$152.8M2.18%4,869,798CommonSOLE
G01767105ALKSALKERMES PLC$134.0M1.91%4,682,289CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$133.5M1.90%1,062,072CommonSOLE
87650L103TARSTARSUS PHARMACEUTICALS INC$126.1M1.80%3,111,680CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$117.8M1.68%2,712,097CommonSOLE
574795100MASIMASIMO CORP$114.9M1.64%683,294CommonSOLE
G31249108ESTAESTABLISHMENT LABS HLDGS INC$110.4M1.57%2,584,131CommonSOLE
46120E602ISRGINTUITIVE SURGICAL INC$110.0M1.57%202,456CommonSOLE
23282W605CYTKCYTOKINETICS INC$89.9M1.28%2,721,158CommonSOLE
74834L100DGXQUEST DIAGNOSTICS INC$89.8M1.28%500,000CommonSOLE
N90064101QUREUNIQURE NV$71.9M1.02%5,158,231CommonSOLE
G3855L106GHRSGH RESEARCH PLC$67.5M0.96%5,540,457CommonSOLE
M96088105URGNUROGEN PHARMA LTD$62.3M0.89%4,543,895CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$62.1M0.88%1,707,402CommonSOLE
002824100ABTABBOTT LABS$60.4M0.86%444,000CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$58.2M0.83%5,123,525CommonSOLE
877619106TSHATAYSHA GENE THERAPIES INC$57.8M0.82%25,021,584CommonSOLE
00773J202SYRESPYRE THERAPEUTICS INC$54.2M0.77%3,621,996CommonSOLE
08659B102BBNXBETA BIONICS INC$48.0M0.68%3,299,191CommonSOLE
36266G107GEHCGE HEALTHCARE TECHNOLOGIES I$46.4M0.66%626,000CommonSOLE
40131M109GHGUARDANT HEALTH INC$44.6M0.63%856,501CommonSOLE
156944100CGONCG ONCOLOGY INC$44.2M0.63%1,701,216CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$43.3M0.62%17,687,772CommonSOLE
N44445109IMTXIMMATICS N.V$37.5M0.53%6,970,152CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$35.6M0.51%424,408CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$35.0M0.50%741,090CommonSOLE
88023B103TEMTEMPUS AI INC$25.4M0.36%400,000CommonSOLE
52635N103LENZLENZ THERAPEUTICS INC$25.3M0.36%863,389CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$23.0M0.33%8,221,929CommonSOLE
68572M106OBIOORCHESTRA BIOMED HLDGS INC$22.3M0.32%8,306,062CommonSOLE
687604108ORKAORUKA THERAPEUTICS INC$21.8M0.31%1,945,649CommonSOLE
64135M105NGNENEUROGENE INC$20.4M0.29%1,362,456CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$20.1M0.29%1,529,836CommonSOLE
282559103ETNBGBP89BIO INC$19.3M0.28%1,967,527CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$19.2M0.27%2,065,010CommonSOLE
98401F105XNCRXENCOR INC$18.9M0.27%2,402,883CommonSOLE
92337C203VSTMVERASTEM INC$17.6M0.25%4,251,616CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$16.1M0.23%1,690,567CommonSOLE
008064206JBIOJADE BIOSCIENCES INC$14.5M0.21%1,449,273CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$13.4M0.19%467,000CommonSOLE
230031106CGEMCULLINAN THERAPEUTICS INC$12.8M0.18%1,705,960CommonSOLE
30068X103XGNEXAGEN INC$11.8M0.17%1,696,866CommonSOLE
75382E208RAPTRAPT THERAPEUTICS INC$11.8M0.17%1,470,499CommonSOLE
221015100CRVSCORVUS PHARMACEUTICALS INC$10.7M0.15%2,679,479CommonSOLE
G70077105PCSCPERCEPTIVE CAP SOLUTIONS COR$7.9M0.11%742,500CommonSOLE
23284F105CTMXCYTOMX THERAPEUTICS INC$7.9M0.11%3,461,500CommonSOLE
02008G201ALURALLURION TECHNOLOGIES INC$6.2M0.09%2,542,603CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$5.8M0.08%900,000CommonSOLE
14179K101CRGXCARGO THERAPEUTICS INC$5.0M0.07%1,212,562CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$4.9M0.07%2,506,102CommonSOLE
68170A108OMDAOMADA HEALTH INC$3.7M0.05%200,000CommonSOLE
G52441105KMTSKESTRA MED TECHNOLOGIES LTD$3.3M0.05%200,000CommonSOLE
15678C102CBLLCERIBELL INC$2.8M0.04%150,000CommonSOLE
88032L605TENXTENAX THERAPEUTICS INC$2.2M0.03%378,346CommonSOLE
4525EP101VTLUSDIMMUNIC INC$280,4700.00%402,107CommonSOLE
00534B100ADGMADAGIO MED HLDGS INC$272,1690.00%209,361CommonSOLE
77313F114RCKTWROCKET PHARMACEUTICALS INC$10,0800.00%350,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.